Ruxolitinib may be the only approved therapy for myelofibrosis (MF). using a JAK inhibitor and was securely coupled with hypomethylating providers in individuals with raised blasts. Median general survival was two years; 10 individuals transformed to severe leukemia. Its make use of in conjunction with additional active providers should be additional explored in medical research.… Continue reading Ruxolitinib may be the only approved therapy for myelofibrosis (MF). using